I agree that this site is using cookies. You can find further informations here.
X
Delforge, Michel
374  results:
Search for persons X
?
1

Belantamab mafodotin: an important treatment option for vul..:

Mateos, Maria Victoria ; Weisel, Katja ; Terpos, Evangelos...
Haematologica.  , 2024
Link: https://doi.org/10.3324/..
 
?
2

The Phase 2 Cartitude-2 Trial: Updated Efficacy and Safety ..:

Hillengass, Jens ; Cohen, Adam D. ; Agha, Mounzer...
Transplantation and Cellular Therapy.  30 (2024)  2 - p. S36-S37 , 2024
Link: https://doi.org/10.1016/..
 
?
3

Proliferative glomerulonephritis with monoclonal immunoglob..:

Verbinnen, Margo ; Sprangers, Ben ; Abrahams, Alferso C...
Nephrology Dialysis Transplantation.  39 (2024)  5 - p. 888-892 , 2024
Link: https://doi.org/10.1093/..
 
?
4

Bortezomib, thalidomide, and dexamethasone with or without ..:

Moreau, Philippe ; Hulin, Cyrille ; Perrot, Aurore...
The Lancet Oncology.  , 2024
Link: https://doi.org/10.1016/..
 
?
5

Plain language summary of the KarMMa-3 study of ide-cel or ..:

Rodriguez-Otero, Paula ; Ailawadhi, Sikander ; Arnulf, Bertrand...
Future Oncology.  , 2024
Link: https://doi.org/10.2217/..
 
?
6

Teclistamab Improves Patient-Reported Symptoms and Health-R..:

Martin, Thomas G. ; Moreau, Philippe ; Usmani, Saad Z....
Clinical Lymphoma Myeloma and Leukemia.  24 (2024)  3 - p. 194-202 , 2024
Link: https://doi.org/10.1016/..
 
?
7

Health-related quality of life in patients with triple-clas..:

Delforge, Michel ; Patel, Krina ; Eliason, Laurie...
The Lancet Haematology.  11 (2024)  3 - p. e216-e227 , 2024
Link: https://doi.org/10.1016/..
 
?
8

Outcome of Second Primary Malignancies Developing in Multip..:

Avivi, Irit ; Vesole, David H. ; Davila-Valls, Julio...
Cancers.  15 (2023)  17 - p. 4359 , 2023
Link: https://doi.org/10.3390/..
 
?
9

MM-163 Long-Term Follow-Up From MajesTEC-1 of Teclistamab, ..:

van de Donk, Niels ; Moreau, Philippe ; Garfall, Alfred...
Clinical Lymphoma Myeloma and Leukemia.  23 (2023)  - p. S477-S478 , 2023
Link: https://doi.org/10.1016/..
 
?
10

Measurable Residual Disease Testing in Multiple Myeloma Rou..:

Ramasamy, Karthik ; Avet-Loiseau, Hervé ; Hveding Blimark, Cecilie...
HemaSphere.  7 (2023)  9 - p. e942 , 2023
Link: https://doi.org/10.1097/..
 
?
11

S195: IDECABTAGENE VICLEUCEL (IDE-CEL) VS STANDARD REGIMENS..:

Patel, Krina ; Rodríguez-Otero, Paula ; Manier, Salomon...
HemaSphere.  7 (2023)  S3 - p. e369897b , 2023
Link: https://doi.org/10.1097/..
 
?
12

POSTER: CT-356 Idecabtagene Vicleucel (ide-cel) Versus Stan..:

Giralt, Sergio ; Ailawadhi, Sikander ; Arnulf, Bertrand...
Clinical Lymphoma Myeloma and Leukemia.  23 (2023)  - p. S232 , 2023
Link: https://doi.org/10.1016/..
 
?
13

PB2114: BELANTAMAB MAFODOTIN FOR RELAPSED/REFRACTORY MULTIP..:

Hultcrantz, Malin ; Kleinman, David ; Vij, Ravi...
HemaSphere.  7 (2023)  S3 - p. e20009f4 , 2023
Link: https://doi.org/10.1097/..
 
?
14

3208 – UNRAVELLING DRUG RESISTANCE AND SENSITIZATION TO PRO..:

Vlayen, Sophie ; Caruso, Marino ; De Keersmaecker, Kim..
Experimental Hematology.  124 (2023)  - p. S153 , 2023
Link: https://doi.org/10.1016/..
 
?
15

Prevention and management of adverse events during treatmen..:

Ludwig, Heinz ; Terpos, Evangelos ; van de Donk, Niels...
The Lancet Oncology.  24 (2023)  6 - p. e255-e269 , 2023
Link: https://doi.org/10.1016/..
 
1-15